Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study.

Objective: There have been no endpoint studies with statins for patients with severe renal failure. The purpose of this prospective, open, randomized, controlled study was to investigate whether atorvastatin (10 mg/day) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 (creatinine clearance < 30 ml/min).

Material And Methods: The study subjects comprised 143 patients who were randomized either to placebo (controls; n=73; mean age 69.

Minimized weight gain between hemodialysis contributes to a reduced risk of death.

Unlabelled: The risk of death is higher in dialysis patients compared to age matched healthy subjects, the main reason being cardiovascular. This prospective study investigated if the extent of ultrafiltration was of importance for the outcome.

Material And Methods: 88 hemodialysis patients were included and followed prospectively.

Safety and efficacy of atorvastatin in patients with severe renal dysfunction.

Objective: To investigate the efficacy and safety of a daily dose of 10 mg of atorvastatin in patients with chronic kidney disease (CKD) stages 4 and 5 and a glomerular filtration rate of <30 ml/min.

Material And Methods: This was an open, prospective, randomized study. A total of 143 patients were included: 73 were controls and 70 were prescribed 10 mg/day of atorvastatin.

Access in therapeutic apheresis.

Various modes may be used to perform apheresis, such as plasma exchange, plasmapheresis, immunoadsorption, and blood perfusion. The vascular access used for acute procedures may be sufficiently supplied by two peripheral veins or catheters placed in the femoral vein or the right internal jugular vein. For chronic treatment it might be necessary to place an arteriovenous fistula or graft.